Allogene Therapeutics, Inc. ALLO 深 沪
等待开盘 08-17 09:30:00 美东时间
2.05
+0.070
+3.54%
华盛通- 最 高2.08
- 今 开1.96
- 成交量 460.51万股
- 最 低 1.92
- 昨 收 1.98
- 总市值 7.08亿
- 52周最高 4.46
- 市盈率 静 --
- 换手率 1.33%
- 52周最低 1.04
- 委 比 -21.85%
- 总股本 3.45亿
- 历史最高 55.00
- 量 比 0.92
- 振 幅 8.08%
- 历史最低 0.8621
- 每 手 1
- 风险率 0.48%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Allogene Therapeutics Files Prospectus For $500M Offering
Allogene Therapeutics Files Prospectus For $500M Offering
08-13 05:00
Allogene Therapeutics Q2 EPS $(0.13) Beats $(0.17) Estimate, Sales $4.640M Beat $2.222K Estimate
Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.17) by 23.53 percent. This is a 43.48 percent increase over losses of $(0.23) per share from the same period last year. The company reported quarterly sales of $4.640 m...
08-13 04:08
Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update
Allogene Therapeutics reported progress on its pivotal Phase 2 ALPHA3 trial for cema-cel in high-risk LBCL, with strong execution and site activation ahead of schedule, supporting enrollment. The FDA granted RMAT and Fast Track designations for cema-cel following interim data showing high MRD clearance rates. The Phase 1 RESOLUTION trial for ALLO-329 in autoimmune diseases is also advancing with brisk enrollment. The company ended Q2 2026 with $4...
08-12 20:05
Allogene Therapeutics' Cemacabtagene Ansegedleucel Receives FDA's Regenerative Medicine Advanced Therapy, Fast Track Designations To Treat B-Cell Lymphoma
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) and Fast T...
07-29 20:32
Lineage Cell Therapeutics Updates COR1 Corneal Cell Transplant Program; Highlights Scalable Allogeneic Production Via AlloSCOPE Platform And Plans Conference Call Today
Company Will Host Conference Call Today at 4:30 PM ET / 1:30 PM PT COR1 Aims to Provide an "Off the Shelf" Supply of Allogeneic CEnCs for Patients Suffering from Corneal Endothelial Disease Utilizes the Company’s AlloSCOPE™ 5D Manufacturing Process, Featuring Seamless, Bioreactor-based Expansion and...
07-13 20:08
Sana Biotechnology To Present Data From Allogeneic Primary Islet Cell Therapy At European Association For The Study Of Diabetes
Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced a symposium presentation highlighting clinical data from an investigator-sponsored, first-in-human study transplanting UP421, an allogeneic primary islet cell th...
07-01 21:05
Allogene Launches ATM Offering to Bolster Capital Flexibility
Allogene Therapeutics ( ($ALLO) ) has issued an update. At its June 18, 2026 an...
06-23 04:54
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation
TScan Therapeutics reported positive interim data from Cohort C of its ALLOHA™ Phase 1 study for TSC-101, a TCR-T therapy for preventing relapse in patients with hematologic malignancies after allo-HCT. Of 14 patients who received TSC-101, 11 achieved complete donor chimerism within three weeks, and two additional patients showed improving chimerism. The therapy was well-tolerated, with safety consistent with post-HCT adverse events. The company ...
06-22 11:00
Cellectis Gains FDA RMAT Status for Allogeneic CAR-T lasme-cel in r/r B-ALL
An announcement from Cellectis SA ( ($CLLS) ) is now available. On June 9, 2026...
06-10 05:09
Artiva Biotherapeutics Announces Clinical, Safety And Translational Data For AlloNK, Its Allogeneic, Non-Genetically Modified Natural Killer Cell Therapy Candidate
Multiple EULAR presentations reinforce potential of AlloNK to drive deep B-cell depletion and meaningful clinical responses across refractory rheumatoid arthritis, Sjögren disease and systemic
06-08 18:34
